INTRODUCTION {#s1}
============

Cyclins are key regulatory components of the cyclin/CDK (Cyclin-Dependent Kinase) complex that regulate the cell cycle, thus contributing to tumor progression. While cyclin D interacts with CDK4/6, cyclin E interacts with CDK2 to form complexes that play a central role in the G1/S transition of the cell cycle. This complex formed by cyclins and CDKs act by phosphorylating Rb \[[@R1], [@R2]\], which releases E2F from the complex, allowing it to activate cell cycle progression, Figure [1](#F1){ref-type="fig"}. Amplifications of cyclin genes are amongst the most common alterations in cancers, with *cyclin D1* (*CCND1*) amplification rates ranging from 15--40% \[[@R1]\].

![Effects of cyclins on cell cycle\
By interacting with CDKs, cyclins form complexes (cyclin D with CDK4/6 and cyclin E with CDK2) that phosphorylate Rb1 (phosphorylated Rb1 is inactive). The Rb protein is a tumor suppressor that plays a pivotal role in the negative control of the cell cycle; Rb1 loss of function is frequently observed in cancer \[[@R48]\]. When Rb1 is phosphorylated, E2F is released and can transcriptionally activate its target genes, enabling the G1/S transition of cell cycle. Cyclin D1 (CCND1) can also be regulated at the transcription level by the RAS-MEK-ERK pathway and at the translation level by mTOR via S6K and 4EBP1 \[[@R11], [@R12], [@R16], [@R17]\]. mTOR inhibitors may attenuate CCND1 action by decreasing translation of CCND1. CDK4/6 inhibitors may attenuate the effects of this pathway as well, especially in the presence of CDK4/6 amplification or CDKN2A/B loss (since CDKN2A/B inhibits CDK4/6 activity). Patients with Rb1 loss or mutations would be expected to be resistant to agents such as mTOR or CDK4/6 inhibitors that act more proximally.](oncotarget-06-3033-g001){#F1}

*Cyclin D1* or *CCND1* was initially designated *PRAD1* or *BCL1*. *PRAD1* was found to be clonally rearranged on chromosome 11q13 with *PTH* (parathyroid hormone) in parathyroid adenomas, resulting in overexpression of cyclin D1 \[[@R3]--[@R5]\]. Similarly, in mantle cell lymphomas, *BCL-1* (B-Cell lymphoma-1) is rearranged and juxtaposes *BCL-1* and the immunoglobulin heavy chain *IGH* (t(11;14)(q13;q32)) resulting in overexpression of the BCL-1 (CCND1) protein \[[@R6], [@R7]\].

*CCND1* amplifications have been described in head and neck carcinomas, non-small-cell lung, endometrial, pancreatic, breast, as well as colorectal cancers \[[@R1]\]. Of interest, in addition to direct *CCND1* amplification, and rearrangement as described above, CCND1 can be overexpressed through several other mechanisms. Activation of the RAS-MEK-ERK pathway, along with ERBB2 in hormonal-driven cancers (such as breast) and the Wnt pathway \[[@R8]--[@R10]\] have also been associated with higher CCND1 expression, that may occur through increasing its transcription \[[@R11], [@R12]\]. The PI3K-AKT-mTOR pathway also regulates *CCND1* translation mechanisms \[[@R13]--[@R15]\] via mTOR and phosphorylation of downstream targets such as 4EBP1 (eukaryotic translation initiation factor 4E) and S6K (ribosomal protein S6 kinase) \[[@R16], [@R17]\] (Figure [1](#F1){ref-type="fig"}).

Cyclins have become increasingly relevant in cancer because drugs that can mitigate their effects are now available. Possible approaches to targeting cyclin-dependent cancers include use of CDK4/CDK6 inhibitors, either alone or in combination. Another approach might include use of mTOR inhibitors, since suppressing mTOR would attenuate the translation of *CCND*1 \[[@R18], [@R19]\]. Of interest in this regard, the mTOR inhibitor temsirolimus is approved in the European Union for the treatment of mantle cell lymphoma, a disease whose hallmark is *CCND1/BCL-1* translocation, resulting in overexpression of CCND1 \[[@R20]\].

Though cyclin gene (*CCN*) amplifications are frequently observed in different cancers \[[@R1]\], the biological and clinical implications of these alterations have not been comprehensively studied. Hence, we used next generation sequencing in a population comprising 392 patients with cancer, aiming to elucidate the correlation between *CCN* alterations with clinical characteristics and outcome.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The clinical and demographic characteristics of our patient population (*N* = 392) can be found in Table [1](#T1){ref-type="table"}. The median age of patients at diagnosis was 54 years (CI 95%, 53--56). Women comprised 57% (*N* = 222) of the population. The majority of patients were Caucasian (72%, *N* = 284). The most represented tumor types were gastro-intestinal (23%, *N* = 91), breast (21%, *N* = 81), and brain (14%, *N* = 56) cancers. The molecular testing was performed mainly on the primary tumor (59% of patients, *N* = 218).

###### Clinical characteristics of 392 patients with or without *CCN* amplifications (univariate analysis)

  Characteristics                                                                   Total patients, *N* = 392   CCN wild-type, *N* = 342   CCN amplified, *N* = 50   *P*-value
  --------------------------------------------------------------------------------- --------------------------- -------------------------- ------------------------- ---------------
  **Age at diagnosis (years)**                                                      54.3                        54.4                       52.5                      0.860
   (Median, CI 95%)                                                                 (52.5--56.0)                (52.6--56.3)               (48.8--58.1)              
  **Gender**                                                                                                                                                         **0.009**
   Women                                                                            222                         185 (83%)                  37 (17%)                  
   Men                                                                              170                         157 (92%)                  13 (8%)                   
  **Race**                                                                                                                                                           
   Caucasian                                                                        284                         250 (88%)                  34 (12%)                  0.498
   Other                                                                            57                          47 (82%)                   10 (18%)                  
   Asian                                                                            25                          22 (88%)                   3 (12%)                   0.281
   African American                                                                 12                          12 (100%)                  0                         
   Unknown                                                                          10                          8 (80%)                    2 (20%)                   
   Hispanic                                                                         4                           3 (75%)                    1 (25%)                   
  **Type of cancer**                                                                                                                                                 
   Gastro-intestinal                                                                91                          81 (89%)                   10 (11%)                  0.720
   Breast                                                                           81                          59 (73%)                   22 (27%)                  **\< 0.0001**
   Brain                                                                            56                          56 (100%)                  0                         **0.0004**
   Gynecologic                                                                      33                          31 (94%)                   2 (6%)                    0.287
   Head and neck                                                                    30                          25 (83%)                   5 (17%)                   0.566
   Liquid                                                                           30                          28 (93%)                   2 (7%)                    0.402
   Melanoma                                                                         29                          27 (93%)                   2 (7%)                    0.560
   Lung                                                                             26                          21 (81%)                   5 (19%)                   0.355
   Other[^a^](#tfn-001){ref-type="table-fn"}                                        16                          14 (88%)                   2 (12%)                   1.000
  **Biopsy site used for molecular testing[^b^](#tfn-002){ref-type="table-fn"}:**                                                                                    **0.029**
   Primary                                                                          218                         196 (90%)                  22 (10%)                  
   Metastatic                                                                       149                         122 (82%)                  27 (18%)                  

Ewing sarcoma, carcinoid tumor, sarcomatoid tumor, peripheral nerve sheath tumor, pleiomorphic cell sarcoma (thigh), soft tissue liposarcoma (*N* = 2), soft tissue rhabdomyosarcoma, pleomorphic liposarcoma, and unknown origin (*n* = 7).

For 25 samples, the origin of the biopsy site used for molecular testing was unavailable.

*CCN* alterations and associations with clinical features {#s2_2}
---------------------------------------------------------

Overall, altered cyclin genes (*CCND1, CCND2, CCND3*, and *CCNE1*) were observed in 50 of the 392 patients tested (13%). There were a total of 53 *CCN* alterations found in 50 patients (three patients had two alterations), [Supplemental Figure 1](#SD1){ref-type="supplementary-material"}. All the *CCN* alterations identified were amplifications; the most frequent were *CCND1* amplifications (55%, *N* = 29/53). In a univariate analysis, *CCN* alterations were significantly associated with women (17% vs 8%, women:men; *P* = 0.009). *CCN* alterations were also associated with breast cancer (*N* = 22/81 (27%) of breast cancer cases, *P* \< 0.0001). Of note, no *CCN* alterations was observed in patients with brain cancers (*P* \< 0.001). The biopsy site was more frequently a metastatic site when positive for a *CCN* amplification (18% vs 10%, metastatic vs. primary; *P* = 0.029), Table [1](#T1){ref-type="table"}.

*CCN* amplifications and direct co-alterations {#s2_3}
----------------------------------------------

In the overall population, the median number of molecular alterations per patient was four (range 0--16), and it was significantly higher in patients harboring *CCN* alterations (median of eight alterations compared to three in patients without *CCN* alterations, *P* \< 0.0001). In a univariate analysis, *CCN* alterations were associated with *FGF/FGFR* alterations (amplification/mutations identified in *FGF3/4/6/10/14/19/23* and *FGFR1/2/3/4*) (*P* \< 0.0001), *ZNF217/ZNF703* (*P* \< 0.0001), *AURKA* (*P* = 0.001), *ARFRP1*(*P* = 0.003), *EMSY* (*P* = 0.007), and *MDM2* (*P* = 0.030) amplifications, as well as amplification/mutations in *MET* (*P* = 0.016) or *AKT1/2* (*P* = 0.023), [Supplemental Table 1](#SD1){ref-type="supplementary-material"}.

Multiple logistic regression analysis of factors associated with *CCN* amplifications {#s2_4}
-------------------------------------------------------------------------------------

In a multiple logistic regression model (that included any parameters that were significant (*P* \< 0.05) in univariate analysis), the only variables that remained statistically associated with *CCN* amplifications were aberrations in *FGF/FGFR* (*P* \< 0.0001), *MET* (*P* = 0.003), and *ARFRP1* (*P* = 0.032). The negative association with brain tumors also remained significant (*P* = 0.044) Table [2](#T2){ref-type="table"}.

###### Multiple logistic regression model for clinical characteristics associated with *CCN* amplifications

  Characteristics                                               *P*-Value       Odds Ratio   95% CI
  ------------------------------------------------------------- --------------- ------------ -------------
  **Gender (women vs. men)**                                    0.410           1.58         0.53--4.69
  **Histology**                                                                              
   Breast                                                       0.913           1.06         0.36--3.15
   Brain[^a^](#tfn-003){ref-type="table-fn"}                    **0.044**       0.26         0.05--1.51
  **Site molecular testing (metastatic vs. primary)**           0.248           1.75         0.68--4.52
  **Genomic alterations[^b^](#tfn-004){ref-type="table-fn"}**                                
   *FGF/FGFR*                                                   \< **0.0001**   41.7         15.9--111.1
   *MYC*                                                        0.247           1.93         0.64--5.85
   *ZNF217/703*                                                 0.475           1.70         0.40--7.25
   *MDM2*                                                       0.267           2.67         0.47--15.15
   *AKT1/2*                                                     0.271           2.55         0.48--13.51
   *AURKA*                                                      0.390           3.26         0.22--47.62
   *ARFRP1*                                                     **0.032**       18.9         1.29--250.0
   *MET*                                                        **0.003**       50.0         3.79--689.0
   *EMSY*                                                       0.271           6.25         0.24--166.7

negative association

*FGF/FGFR* comprised amplification/mutations in *FGF3/4/6/10/14/19/23* and *FGFR1/2/3/4*.

*MYC, ZNF217/703, MDM2, AURKA, ARFRP1, EMSY* alterations were all amplifications. *AKT1/2* and *MET* alterations comprised amplification/mutations.

*CCN* extended co-amplification network {#s2_5}
---------------------------------------

We further explored the ramifications of alteration associations, and found, in a multiple logistic regression model, that in addition to its association with *CCN* amplifications (*P* \< 0.0001), *FGF/FGFR* associated strongly with *RICTOR* (*P* \< 0.0001). *FGF/FGFR* also correlated with *ARID1A* (*P* = 0.033), *ZNF217/703* (*P* = 0.019), *MYST3* (*P* = 0.034), and *ARID1A* (*P* = 0.033). *MET* alterations associated with *RICTOR* (*P* = 0.011) and *NFKBIA* (*P* = 0.032), and *ARFRP1* strongly correlated with both *ZNF217/703* (*P* \< 0.0001) and *AURKA* (*P* = 0.006). Lastly, we investigated the associations with *ZNF217/703* amplifications and found strong correlations with *AURKA* (*P* \< 0.0001), *ARFRP1* (*P* = 0.002), *FGF/FGFR* (*P* = 0.004), *ERBB2/3/4* (*P* = 0.044), and *MYST3* (*P* = 0.002), Figure [2A](#F2){ref-type="fig"} and [Supplemental Table 2](#SD1){ref-type="supplementary-material"}.

![*CCN* and co-alterations\
In panel A, the connectors represent a statistically significant association in a multiple logistic regression model (*P* \< 0.05). The double orange connectors represent a correlation with a *P*-value \< 0.0001; in that case, there was chromosomal co-localization (panel B). Cyclin genes were *CCND1, CCND2, CCND3*, and *CCNE1*; *FGF/FGFR* gene family comprised *FGF3/4/6/10/14/19/23* and *FGFR1/2/3/4*; *ERBB* comprised *ERBB2/3/4*; *ZNF* comprised *ZNF217* and *ZNF703*. In panel B, chromosome co-localizations are represented by the same color. Boxes contain genes that are related family members.](oncotarget-06-3033-g002){#F2}

Since the alterations with a very strong association (*P* \< 0.0001) were amplifications, we examined the chromosome location of these genes and found patterns of co-localization in the same chromosome regions. Indeed, the strong association observed between *CCN* and *FGF/FGFR* family genes can be partly explained by the co-localization of *CCND1* and *FGF3/4/19* at the 11q13 locus. Of note, *EMSY*, that correlated with *CCN* alterations in the univariate analysis, is also found at the 11q13 locus. Additionally, *CCND2* and *FGF6/23* are both localized at 12p13. The strong association observed between *FGF/FGFR* and *RICTOR* can be explained by the co-localization of *FGF10* and *RICTOR* at the 5p13 genomic location. *FGFR1*, *ZNF703* and *MYST3* are localized on 8p11 and *ZNF207* was highly co-amplified with *ARFRP1* and *AURKA* at the 20q13 locus, Figure [2B](#F2){ref-type="fig"}.

*CCN* amplifications and clinical outcome {#s2_6}
-----------------------------------------

In a univariate analysis, *CCN* amplifications correlated with the development of metastasis in the liver (*P* = 0.005), bone (*P* = 0.036), and brain (*P* = 0.047), [Supplemental Table 3](#SD1){ref-type="supplementary-material"}. The only association that remained significant in the multiple logistic regression model was the association with the development of liver metastasis (*P* = 0.046). Neither the overall survival, nor the time to metastasis/recurrence were statistically different depending on *CCN* alteration status (HR = 1.17; *P* = 0.646 and HR = 1.08; *P* = 0.691, respectively). No differences in median best progression-free survival time (PFS) or PFS analysis by treatment type was observed when patients with, or without, *CCN* alterations were compared.

Survival analysis in the overall population {#s2_7}
-------------------------------------------

In our population of 392 patients, the median follow up time was 37.8 months (95%CI 30.9--44.8 months). In a univariate analysis, the survival was poorer for patients with gastro-intestinal histology (*P* \< 0.0001), men (*P* = 0.036), or patients harboring a *TP53* (*P* = 0.002), *CDK* (*CDK4/6/2/CDKN2A/2B*) (*P* = 0.005), *PTEN* (*P* \< 0.0001), or *EGFR* (*P* = 0.030) alterations. Of importance, only the gastro-intestinal histology (*P* \< 0.0001), *PTEN* (*P* \< 0.0001), and *CDK* alterations (*P* = 0.041) remained statistically significant independent predictors for poorer survival in a Cox regression model, Table [3](#T3){ref-type="table"}. *TP53* mutational status was no longer a significant predictor of inferior survival, although a trend persisted with *P* = 0.087. *CCN* was not a survival predictor in univariate analysis (*P* = 0.646).

###### Overall survival associations in 392 patients with cancer

  Characteristics                                                   Univariable         Multivariable                       
  ----------------------------------------------------------------- ------------------- --------------- ------------------- ---------------
  **Gender (men vs. women)**                                        0.59 (0.36--0.97)   **0.036**       0.65 (0.38--1.09)   0.107
  **Histology**                                                                                                             
   Gastro-intestinal (*N* = 91)                                     0.19 (0.09--0.37)   \< **0.0001**   0.28 (0.16--0.49)   \< **0.0001**
   Breast (*N* = 80)                                                0.63 (0.37--1.04)   0.073           \-\--               \-\--
   Brain (*N* = 56)                                                 1.23 (0.61--2.49)   0.564           \-\--               \-\--
   Gynecologic (*N* = 33)                                           1.47 (0.64--3.38)   0.359           \-\--               \-\--
   Head & Neck (*N* = 30)                                           0.58 (0.25--1.35)   0.207           \-\--               \-\--
   Liquid (*N* = 29)                                                2.37 (0.94--5.93)   0.065           \-\--               \-\--
   Melanoma (*N* = 29)                                              2.23 (0.99--5.02)   0.053           \-\--               \-\--
   Lung (*N* = 26)                                                  0.53 (0.17--1.65)   0.269           \-\--               \-\--
   Other (*N* = 16)                                                 0.75 (0.16--3.67)   0.722           \-\--               \-\--
  **Genetic alteration type[^a^](#tfn-005){ref-type="table-fn"}**                                                           
   TP53 (*N* = 178)                                                 0.47 (0.29--0.75)   **0.002**       0.64 (0.38--1.01)   0.087
   CDK (*N* = 104)                                                  0.43 (0.24--0.78)   **0.005**       0.56 (0.32--0.98)   **0.041**
   KRAS (*N* = 63)                                                  0.55 (0.27--1.01)   0.089           \-\--               \-\--
   FGF/FGFR (*N* = 57)                                              1.35 (0.74--2.47)   0.324           \-\--               \-\--
   PIK3CA (*N* = 53)                                                1.26 (0.64--2.47)   0.503           \-\--               \-\--
   CCN (*N* = 50)                                                   1.17 (0.60--2.26)   0.645           \-\--               \-\--
   MYC (*N* = 48)                                                   0.68 (0.33--1.41)   0.295                               
   PTEN (*N* = 42)                                                  0.09 (0.03--0.23)   \< **0.0001**   0.19 (0.10--0.36)   \< **0.0001**
   EGFR (*N* = 31)                                                  0.29 (0.09--0.89)   **0.030**       0.95 (0.39--2.29)   0.900
   BRCA1/2 (*N* = 28)                                               0.61 (0.24--1.55)   0.300           \-\--               \-\--
   APC (*N* = 24)                                                   0.30 (0.09--1.00)   0.051           \-\--               \-\--

Included alterations with at least 5 events (death) and *N* = 20 patients with the alteration.

*CCN* comprised *CCND1/2/3* and *CCNE1; CDK* comprised *CDK4/6*, *CDKN2A/B*; *FGF/FGFR* comprised *FGF3/4/6/10/14/19/23* and *FGFR1/2/3/4*. Only characteristics that were significant (*P* \< 0.05) in the univariable analysis (log-rank test) were included in the multivariable analysis (Cox regression model).

DISCUSSION {#s3}
==========

Cyclin amplifications are frequent in cancer. The percentage of cyclin (*CCN*) alteration varies by tumor type; for instance, in previous studies, *CCND1* amplification ranged from 15--40% \[[@R1]\]. Our population had an overall 13% rate of *CCN* alterations, with most (55%) of them being *CCND1* amplifications ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}). We found that *CCN* alterations were associated with breast cancer (27% of cases), which is consistent with the literature \[[@R1], [@R21], [@R22]\]. CCND1 overexpression was previously found to be associated with shorter patient survival in many cancers and is often correlated with increased risk of metastasis \[[@R23], [@R24]\]. In our population, the overall survival was not statistically different in the presence of *CCN* abnormalities, perhaps because of the small number of death events at the time of analysis (*N* = 9 deaths amongst 50 patients with cyclin alterations). In a Cox regression model, the variables independently associated with worse survival were gastrointestinal malignancies, consistent with previous publications in advanced cancer \[[@R25]\], and alterations in *PTEN* as well as *CDK* family genes (Table [3](#T3){ref-type="table"}). Of note, *TP53* alterations were no longer associated with a shorter overall survival, perhaps because of its association with gastrointestinal histology (*P* = 0.024).

We did not detect any difference in best PFS analysis when patients with, or without *CCN* amplifications were compared. Types of therapy examined comprised regimens that included gemcitabine, taxanes, platinums, bevacizumab, hormonal treatments, and everolimus (though the number of patients treated with the latter drug was small, thus limiting the power of the analysis) ([Supplemental Table 3](#SD1){ref-type="supplementary-material"}). Of interest, *CCN* alterations were more frequent in metastatic sites (*p* = 0.029; univariate anlaysis), and there was a higher incidence of these alterations in patients who developed liver metastases (multiple logistic regression analysis; *p* = 0.046) (Tables [1](#T1){ref-type="table"} and [Supplemental Table 3](#SD1){ref-type="supplementary-material"}). Of interest, some previous studies have also described an association between *CCND2* and *CCND3* with liver metastasis \[[@R26], [@R27]\]. Finally, patients harboring *CCN* amplifications had a median of eight molecular alterations compared to three in patients without *CCN* amplifications (*P* \< 0.0001).

Of importance, we uncovered an extended network of co-amplifications in our study. Indeed, *CCN* gene amplifications correlated independently with *FGF/FGFR* (*P* \< 0.0001), *ARFRP1* (membrane associated GTPase) (*p* = 0.032) and *MET* alterations (*P* = 0.003) in a multiple logistic regression analysis. The association between *CCN* and *FGFs* is not surprising, considering that *CCND1* and *FGF3*, *4* and *19* co-localize on the same amplicon on chromosome 11q13 \[[@R28]\]. Similarly, *CCND2* and *FGF6* and *23* co-localize on 12p13. A systematic dissection of the genomic associations at different levels (first and second level of association with *CCN* amplifications, Figure [2](#F2){ref-type="fig"}) revealed a more comprehensive network. Indeed, the co-localization involving *FGFR1* and *ZNF703* has been described \[[@R29]\], consistent with the univariate association between amplifications in *CCN* (which correlates with *FGF/FGFR* aberrations) and *ZNFs*. (*ZNF* products are zinc finger proteins, which bind DNA and, through this binding, regulate gene transcription). *ZNF703*, like *FGFR1*, is localized at the 8p11 locus and there is compelling evidence that *ZNF703* is one of the driver genes in this amplified region \[[@R30]\], especially in breast cancers where *ZNF703* expression seems to be induced by estrogens \[[@R31]\]. *FGFR1* was the first reported oncogene in the 8p11 region, and its amplification and overexpression has been related to poor prognosis and endocrine resistance in breast cancer \[[@R32]\].

Relationships between cyclins and FGF/FGFRs have also been previously reported at the protein level. For instance, a study showed that FGFR4 contributed to the maintenance of CCND1 via the mTOR translation pathway, and several other studies demonstrated cooperation between FGFR and CCND1 \[[@R33]\]. Further, CCND1 can enhance tumor progression, at least in part, by an increased level of transcription of FGFR1 and FGFR2 via E2F \[[@R34]\]. In addition, Kwek et al. \[[@R29]\] suggested that CCND1 induced ZNF703 via the Rb/E2F pathway.

*ZNF217* is localized on 20q13 and can be responsible for enhanced AKT phosphorylation \[[@R35]\]. Of interest, ZNF217 was identified as a marker of poor prognosis in breast cancer \[[@R36]\], was shown to drive epithelial-mesenchymal transition and invasion \[[@R36]\], as well as enhance ERBB3 transcription; the latter is required for ERBB2-dependent breast tumor proliferation, since the ERBB2-ERBB3 heterodimer is the functional "oncogenic unit" \[[@R37]\].

While little is known about ADP-ribosylation factor-related protein 1 gene (*ARFRP1*, anomalies of which correlated with those in *CCN* in multiple logistic regression analysis) and cancer \[[@R38]\], *AURKA*, (Aurora A kinase), which co-localizes with *ARFRP1* and with *ZNF217* on 20q13, appears to be more well characterized and is believed to control the G2/M transition \[[@R39]\]. Anomalies in *AURKA* and *CCN* correlated in our study in a univariate analysis. Finally, *MET* anomalies (which correlated with *CCN* amplifications; multiple logistic regression analysis) correlated with *RICTOR* abnormalities *(*univariate analysis), which in turn co-localized with *FGF10* on 5p13. RICTOR is a component of the second mTOR complex, identified as mTORC2. The mTORC2 can phosphorylate protein kinases including AKT and PKCα, turning on a variety of cellular processes such as proliferation and survival \[[@R40]\].

These co-alterations might, to a certain extent, provide a selective advantage to the tumor. One possibility is that the multiple amplifications in this network cooperate synergistically to increase pathway activation and hence the likelihood of proliferation. Another could be that the contribution of each component to functions other than the cell cycle control may offer an additional selective advantage during oncogenesis. In addition, several studies demonstrated that *CCND1* amplifications were linked to resistance mechanisms, such as endocrine resistance in breast cancers \[[@R41], [@R42]\], or BRAF inhibitor resistance in *BRAF* V600E mutated melanomas \[[@R43]\]. Further, *CCND1* has also been implicated in acquired radioresistance \[[@R44]\].

Importantly, cyclins have been correlated with positive estrogen receptor (ER+) in breast cancers \[[@R28]\]. In our population, we observed that 31% (17/53) of breast specimens that were ER+ also harbored a *CCN* amplification. Due to the availability of anti-estrogen therapies, ER positivity is considered a marker of good prognosis. However, among patients with ER positive tumors, those also harboring *CCND1* amplification seem to constitute a subgroup with higher grade and a relatively poor prognosis \[[@R45], [@R46]\]. Recently, the randomized phase 2 trial PALOMA-1 investigating the CDK4/6 inhibitor palbociclib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared to letrozole alone (20.2 vs. 10.2 months, *P* = 0.0004) in women with ER+/HER2- metastatic breast cancer \[[@R47]\].

Our study had several limitations. First, correlations were made via a retrospective review. As such, the timing of response assessment was performed per the discretion of the attending physician and not completely uniform. Second, diverse histologies were included, and in some there were relatively small numbers of patients. On the other hand, these findings could imply that the impact of cyclin amplifications and co-amplification network is important across histologies. Finally, the molecular testing was done on biopsies obtained at different time points during the clinical course (median of nine months after diagnosis, CI 95% 6--14 months).

*CCN* amplifications appear to have biological implications, including an association with liver metastases, and patterns of molecular correlations, such as those between *CCN* aberrations and *FGF/FGFR* amplifications, as well as *MET* and *ARFRP1* alterations. Further, patients harboring *CCN* amplifications had significantly higher numbers of molecular alterations. The ramifications of a co-amplification network are that these gene products may work together during tumor progression and require tailored combination therapies. As several oncogenic pathways seem to converge on the cyclin-associated pathway and cell cycle progression, the use of drugs to target the cyclin pathway, including CDK4/6 inhibitors, or mTOR inhibitors, have become increasingly relevant, particularly in combinations that can be appropriately customized to attenuate resistance mechanisms.

METHODS {#s4}
=======

Patients {#s4_1}
--------

We retrospectively reviewed the clinicopathology and clinical outcomes of 392 patients with advanced cancer (solid and hematologic tumors were considered) who were seen at the UC San Diego Moores Cancer Center and for whom molecular testing had been performed between October 2012 and April 2014. This study was performed and consents obtained in accordance with UCSD Institutional Review Board guidelines.

Next generation sequencing {#s4_2}
--------------------------

Next generation sequencing was performed by Foundation Medicine (FoundationOne™, Cambridge, Massachusetts, <http://www.foundationone.com>), which is a clinical grade CLIA-approved next-generation sequencing test that sequences the entire coding sequence of 236 cancer-related genes and 47 introns from 19 genes often rearranged in cancer (full list available at <http://foundationone.com/genelist1.php>). (Nine patients (2.3%) were tested with an earlier version of the panel comprising 182 cancer--related genes). Gene chromosome localization were found using the "genecards" database (<http://www.genecards.org/>). For the purposes of this analysis, cyclin gene (*CCN*) status was examined for *CCND1, CCND2, CCND3*, and *CCNE1*.

Statistical analysis {#s4_3}
--------------------

Patients\' characteristics were summarized using descriptive statistics. Associations between categorical variables was done using Fisher\'s exact tests. Time to metastasis/recurrence was defined as the time interval between diagnosis and first metastasis/recurrence, whichever came first. Overall survival (OS) was defined as the time from diagnosis to death or last follow-up date for patients who were alive. Progression-free survival (PFS) was defined as the time from the beginning of a given therapy to progression or treatment discontinuation for any reason. The data for best progression-free survival was available for 246 patients of 392 (63%). Best PFS was defined as the longest PFS achieved on treatment. Patients who did not progress were censored at the last follow up date. Estimations for OS and PFS were done using a Kaplan-Meier analysis, and were compared among subgroups by the log-rank test. Cox regression model were fit to assess the association between OS and patients\' characteristics and *CCN* alteration status. Multiple logistic regressions were fit to analyze the association between *CCN* alterations and other patients\' characteristics. Only variables with *P*-values less than 0.05 were included in the multiple regression models. All statistical analysis were performed by MS with SPSS version 22.0.
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